This study investigates the impact of the age at which HIV was acquired on adherence.
This study aimed to describe the frequency of virologic factors that previously influenced the efficacy of this treatment, namely RPV and CAB resistance-associated mutations.
Long-acting injectable (LAI) antiretroviral therapy (ART) has the potential to improve medication adherence, reduce human immunodeficiency virus (HIV) stigma, and promote equity in care outcomes among people with HIV (PWH). We describe our early experience implementing LAI-cabotegravir/rilpivirine (CAB/RPV) for maintenance HIV-1 treatment.
The CUSTOMIZE hybrid III implementation-effectiveness study evaluated implementation of once-monthly long-acting (LA) cabotegravir + rilpivirine in diverse US healthcare settings. Here, we report patient participant perspectives after 12 months in CUSTOMIZE.
CUSTOMIZE evaluated the implementation of long-acting (LA) cabotegravir + rilpivirine, a novel healthcare provider–administered injectable antiretroviral therapy regimen, in diverse US healthcare settings. Findings from staff-study participants (SSPs) through 12 months of implementation are reported.
The approval of intramuscular cabotegravir (CAB) and rilpivirine (RPV) offers a new therapeutic modality with the opportunity of a longer dosing frequency. The data from recent trials including FLAIR and ATLAS have shown non-inferiority in treatment based on the current standard of care. This approval has the potential to simplify patient medication regimens, while maintaining
This study aimed to estimate the cost-effectiveness of long-acting injectable cabotegravir compared with tenofovir disoproxil fumarate and emtricitabine in South Africa, using methods standard to government planning, and to determine the threshold price at which long-acting injectable cabotegravir is as cost-effective as tenofovir disoproxil fumarate and emtricitabine.
Findings indicate that, while the overall number of people testing positive for HIV following CAB-LA PrEP is extremely low, approximately one in four persons diagnosed with HIV carried a virus resistant to DTG.
Malabsorption in patients with HIV (PWH) can lead to decreased antiretroviral (ARV) drug exposure which may induce viral failure and emergence of resistance mutations When treating PWH with malabsorption, it is important to avoid oral administration of antiretroviral therapies (ARTs) and switch them to parenteral agents, which bypass the gastrointestinal system
While there are increased opportunities for transplant, PWH have added layers of complexity relating to resistance profiles and drug-drug interactions (DDIs) between their antiretroviral (ARV) regimen and the immunosuppressive medications required to prevent organ rejection. • Ibalizumab (IBA), a CD4-directed post-attachment HIV-1 inhibitor, received US approval in 2018 as the first long-acting antiretroviral and monoclonal
